首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1
【2h】

Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1

机译:p38激活和线粒体参与特异于TRAIL受体1的人源单克隆抗体Fab诱导的人白血病细胞死亡。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death with minimal damage to normal cells; however, some cancer cells are resistant to TRAIL. TRAIL resistance may be overcome by agonistic antibodies to TRAIL receptors. In this study, we report the toxic effects of a novel recombinant agonistic human anti–TRAIL receptor 1 (DR4) monoclonal antibody Fab fragment, DR4-4, on various TRAIL-resistant and -sensitive cancer cell lines. The mechanisms of DR4-4 Fab–induced cell death in a human T cell leukemia cell line (Jurkat) were investigated using cell viability testing, immunoblotting, immunoassays, flow cytometry, and morphological observation. DR4-4 Fab–induced caspase-independent necrosis was observed to occur in Jurkat cells in association with p38 mitogen-activated protein kinase activation, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein degradation, decreased mitochondrial membrane potential, and increased mitochondrial reactive oxygen species production. Increased cytotoxic effects of DR4-4 Fab were observed in combination with TRAIL or γ-irradiation. Our results indicate that the novel DR4-4 Fab might overcome TRAIL-resistance and induce death in leukemia cells via cellular mechanisms different from those activated by TRAIL. DR4-4 Fab may have application as a potential therapeutic antibody fragment in single or combination therapy for cancer.
机译:肿瘤坏死因子相关的凋亡诱导配体(TRAIL)诱导癌细胞死亡,对正常细胞的损害最小。然而,一些癌细胞对TRAIL具有抗性。可以通过针对TRAIL受体的激动性抗体克服TRAIL抗性。在这项研究中,我们报告了新型重组激动人抗TRAIL受体1(DR4)单克隆抗体Fab片段DR4-4对多种TRAIL耐药和敏感性癌细胞系的毒性作用。使用细胞活力测试,免疫印迹,免疫测定,流式细胞仪和形态学观察,研究了DR4-4 Fab诱导的人类T细胞白血病细胞系(Jurkat)中细胞死亡的机制。在Jurkat细胞中观察到DR4-4 Fab诱导的caspase非依赖性坏死与p38丝裂原活化的蛋白激酶活化,细胞FLICE(FADD样IL-1β转化酶)抑制蛋白降解,线粒体膜电位降低有关,并增加线粒体活性氧的产生。与TRAIL或γ辐射联合使用时,观察到DR4-4 Fab的细胞毒性作用增强。我们的结果表明,新型DR4-4 Fab可能通过不同于TRAIL激活的细胞机制,克服了TRAIL耐药性并诱导白血病细胞死亡。 DR4-4 Fab可作为潜在的治疗性抗体片段应用于癌症的单一或联合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号